< Back to previous page


Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice.

Journal Contribution - Review Article

Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardization regarding the CRS, we are still lacking a much-needed standardization among the various IP chemotherapy treatment modalities used today in clinical practice. Pharmacologic evidence should be generated to answer important questions raised by the myriad of variables associated with IP chemotherapy.
Journal: Pleura and Peritoneum
ISSN: 2364-768X
Issue: 2
Volume: 2
Pages: 63 - 72
Publication year:2017
Keywords:bidirectional intraoperative chemotherapy (BIC), early postoperative intraperitoneal chemotherapy (EPIC), hyperthermic intraperitoneal chemotherapy (HIPEC), peritoneal surface malignancy